AR003415A1 - Compuestos analogos de lactacistina, metodo para inhibir la proteolisis dependiente de proteasoma, metodo para identificar un proceso biologico mediado por proteolisis dependiente de proteasoma, uso de dichos compuestos para preparar un medicamento para tratar una condicion mediada por proteolisis dependiente de proteasoma. - Google Patents
Compuestos analogos de lactacistina, metodo para inhibir la proteolisis dependiente de proteasoma, metodo para identificar un proceso biologico mediado por proteolisis dependiente de proteasoma, uso de dichos compuestos para preparar un medicamento para tratar una condicion mediada por proteolisis dependiente de proteasoma.Info
- Publication number
- AR003415A1 AR003415A1 ARP960102190A AR10219096A AR003415A1 AR 003415 A1 AR003415 A1 AR 003415A1 AR P960102190 A ARP960102190 A AR P960102190A AR 10219096 A AR10219096 A AR 10219096A AR 003415 A1 AR003415 A1 AR 003415A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- proteolisis
- proteasoma
- proaroid
- lactacistin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
Abstract
Compuestos análogos de la lactacistina que tiene la fórmula (I), en donde Z1, Z2, A1, R2, L0 y X1 tienen los significados dados en la memoria descriptiva;un método para inhibir proteólisis, un método para identificar un proceso biológico y usode los compuestos para la preparación de un medicamento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/421,583 US6335358B1 (en) | 1995-04-12 | 1995-04-12 | Lactacystin analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
AR003415A1 true AR003415A1 (es) | 1998-08-05 |
Family
ID=23671162
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960102190A AR003415A1 (es) | 1995-04-12 | 1996-04-12 | Compuestos analogos de lactacistina, metodo para inhibir la proteolisis dependiente de proteasoma, metodo para identificar un proceso biologico mediado por proteolisis dependiente de proteasoma, uso de dichos compuestos para preparar un medicamento para tratar una condicion mediada por proteolisis dependiente de proteasoma. |
ARP980101316A AR014619A2 (es) | 1995-04-12 | 1998-03-23 | Composiciones farmaceuticas que contienen analogos de lactacistina, y los usos de los mismos para la manufactura de un medicamento |
ARP980101367A AR011204A1 (es) | 1995-04-12 | 1998-03-25 | Compuestos analogos de lactacistina, composicion farmaceutica, uso de los mismos para la preparacion de un medicamento y metodo para inhibir laproteolisis dependiente de proteasoma |
ARP980101368A AR012172A2 (es) | 1995-04-12 | 1998-03-25 | Composiciones farmaceuticas que comprenden analogos de lactacistina y uso de los mismos para la fabricacion de un medicamento |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980101316A AR014619A2 (es) | 1995-04-12 | 1998-03-23 | Composiciones farmaceuticas que contienen analogos de lactacistina, y los usos de los mismos para la manufactura de un medicamento |
ARP980101367A AR011204A1 (es) | 1995-04-12 | 1998-03-25 | Compuestos analogos de lactacistina, composicion farmaceutica, uso de los mismos para la preparacion de un medicamento y metodo para inhibir laproteolisis dependiente de proteasoma |
ARP980101368A AR012172A2 (es) | 1995-04-12 | 1998-03-25 | Composiciones farmaceuticas que comprenden analogos de lactacistina y uso de los mismos para la fabricacion de un medicamento |
Country Status (16)
Country | Link |
---|---|
US (6) | US6335358B1 (es) |
EP (1) | EP0820283B1 (es) |
JP (1) | JP4153032B2 (es) |
KR (1) | KR100493472B1 (es) |
CN (1) | CN1151787C (es) |
AR (4) | AR003415A1 (es) |
AT (1) | ATE353644T1 (es) |
AU (1) | AU705791C (es) |
CA (1) | CA2217817A1 (es) |
DE (1) | DE69636902T2 (es) |
ES (1) | ES2283001T3 (es) |
HK (1) | HK1008489A1 (es) |
IL (1) | IL117887A (es) |
NZ (1) | NZ306775A (es) |
WO (1) | WO1996032105A1 (es) |
ZA (1) | ZA962933B (es) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US6838477B2 (en) * | 1995-04-12 | 2005-01-04 | President And Fellows Of Harvard College | Lactacystin analogs |
CN1159061C (zh) * | 1997-02-15 | 2004-07-28 | 千年药物公司 | 通过nf-kappab的抑制治疗梗塞 |
US6133308A (en) | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
AU9580098A (en) * | 1997-09-25 | 1999-04-12 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
CA2219867A1 (en) * | 1997-10-31 | 1999-04-30 | Jiangping Wu | The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
US5902818A (en) * | 1997-12-09 | 1999-05-11 | Auburn University | Surface active N-halamine compounds |
US6469177B1 (en) | 1997-12-09 | 2002-10-22 | Auburn University | Surface active N-Halamine compounds |
EP0943624A1 (en) * | 1998-03-12 | 1999-09-22 | Universiteit Utrecht | Peptidic inhibitors of down-regulation of growth hormone receptor |
FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
US6902721B1 (en) * | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6462019B1 (en) * | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
NZ511197A (en) * | 1998-10-20 | 2003-08-29 | Millenium Pharmaceuticals Inc | Method for monitoring proteasome inhibitor drug action |
US6492333B1 (en) * | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
EP1053750A1 (en) * | 1999-04-22 | 2000-11-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis) |
US6831099B1 (en) * | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
CA2419132A1 (en) * | 2000-08-08 | 2002-02-14 | Antonella Favit | Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway |
DE10040742B4 (de) * | 2000-08-17 | 2006-08-24 | Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin | Mittel zur Herz-Kreislauf-Protektion |
WO2002030455A2 (de) * | 2000-10-12 | 2002-04-18 | Viromics Gmbh | Mittel zur behandlung von virus-infektionen |
WO2002047610A2 (en) * | 2000-11-16 | 2002-06-20 | The Regents Of The University Of California | Marine actinomycete taxon for drug and fermentation product dicovery |
EP1346225A2 (en) * | 2000-12-22 | 2003-09-24 | Boehringer Ingelheim Pharma GmbH & Co.KG | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
WO2002080907A1 (en) * | 2001-04-03 | 2002-10-17 | Millennium Pharmaceuticals, Inc. | Combination of lactacystin analog and immunosuppressive drug for the prolongation of allograft survival |
ATE333273T1 (de) | 2001-05-21 | 2006-08-15 | Alcon Inc | Verwendung von nf-kappa.b inhibitoren zur behandlung von augentrockenheit |
US7112588B2 (en) | 2001-05-21 | 2006-09-26 | Alcon, Inc. | Use of proteasome inhibitors to treat dry eye disorders |
US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
WO2002094311A1 (en) | 2001-05-21 | 2002-11-28 | Alcon, Inc. | Use of proteasome inhibitors to treat dry eye disorders |
US6645994B1 (en) | 2001-06-01 | 2003-11-11 | Alcon, Inc. | Method of treating dry eye disorders |
US20040014678A1 (en) * | 2001-08-08 | 2004-01-22 | Antonella Favit | Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway |
US6548054B2 (en) * | 2001-09-06 | 2003-04-15 | Auburn University | Biocidal polystyrene hydantoin particles |
US6969769B2 (en) * | 2002-06-14 | 2005-11-29 | Vanson Halosource, Inc. | N-halamine siloxanes for use in biocidal coatings and materials |
US7179834B2 (en) * | 2002-06-24 | 2007-02-20 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
US7176232B2 (en) | 2002-06-24 | 2007-02-13 | The Regents Of The University Of California | Salinosporamides and methods for use thereof |
US7687072B2 (en) | 2002-10-31 | 2010-03-30 | Auburn University | Biocidal particles of methylated polystyrene |
US20040156854A1 (en) | 2002-12-06 | 2004-08-12 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
DE602004024037D1 (de) * | 2003-02-14 | 2009-12-24 | Intermed Discovery Gmbh | Substituierte heterozyklen |
JP2007523862A (ja) * | 2003-06-20 | 2007-08-23 | ネレアス ファーマシューティカルズ インコーポレイテッド | 癌、炎症及び感染性疾患の治療のための、[3.2.0]複素環式化合物およびそれらの類縁体の使用 |
ZA200600473B (en) * | 2003-06-20 | 2007-04-25 | Univ California | Salinosporamides and methods for use thereof |
US20060052390A1 (en) * | 2003-12-24 | 2006-03-09 | Scios, Inc. | Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition |
EP1715855A4 (en) * | 2004-01-29 | 2010-06-16 | Elixir Pharmaceuticals Inc | ANTIVIRAL DRUGS |
US7371875B2 (en) | 2004-03-12 | 2008-05-13 | Miikana Therapeutics, Inc. | Cytotoxic agents and methods of use |
US7183417B2 (en) * | 2004-04-09 | 2007-02-27 | President And Fellows Of Harvard College | Simple stereocontrolled synthesis of salinosporamide A |
CN103554222A (zh) | 2004-04-15 | 2014-02-05 | 欧尼斯治疗公司 | 用于抑制蛋白酶体酶的化合物 |
US8198270B2 (en) | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US7579371B2 (en) | 2004-04-30 | 2009-08-25 | Nereus Pharmaceuticals, Inc. | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
EP2025679A3 (en) * | 2004-04-30 | 2009-07-08 | Nereus Pharmaceuticals, Inc. | [3.2.0] Heterocyclic compounds and methods of using the same |
SI2030981T1 (sl) | 2004-05-10 | 2014-11-28 | Onyx Therapeutics, Inc. | Spojine za inhibiranje proteasomskega encima |
EP1805208A2 (en) | 2004-10-20 | 2007-07-11 | Proteolix, Inc. | Labeled compounds for proteasome inhibition |
WO2006062732A2 (en) * | 2004-11-19 | 2006-06-15 | Synta Pharmaceuticals Corp. | Compounds acting at the centrosome |
WO2006060676A1 (en) * | 2004-12-03 | 2006-06-08 | Dana Farber Cancer Institute | Compositions and methods for treating neoplastic diseases |
MX2007006523A (es) * | 2004-12-03 | 2007-09-11 | Nereus Pharmaceuticals Inc | Metodos para utilizar compuestos heterociclicos [3.2.0] y sus analogos. |
WO2006118973A2 (en) * | 2005-04-29 | 2006-11-09 | Nereus Pharmaceuticals, Inc. | Methods of using heterobyclic compounds for treatment of rectal cancer |
US7465720B2 (en) * | 2005-09-12 | 2008-12-16 | President And Fellows Of Harvard College | Proteasome inhibiting β-lactam compounds |
US8716322B2 (en) | 2005-11-09 | 2014-05-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
WO2007098139A2 (en) * | 2006-02-21 | 2007-08-30 | The Ohio State University Research Foundation | Anticancer agents |
CN102718776A (zh) | 2006-04-06 | 2012-10-10 | 尼瑞斯药品公司 | Salinosporamide a及其类似物的全合成 |
AU2007261345B2 (en) | 2006-06-19 | 2012-02-23 | Onyx Therapeutics, Inc. | Peptide epoxyketones for proteasome inhibition |
WO2008063513A2 (en) * | 2006-11-13 | 2008-05-29 | Trustees Of Columbia University In The City Of New York | Selective proteasome inhibitors for treating diabetes |
US7824698B2 (en) * | 2007-02-02 | 2010-11-02 | Nereus Pharmaceuticals, Inc. | Lyophilized formulations of Salinosporamide A |
ME02462B (me) | 2007-10-04 | 2017-02-20 | Onyx Therapeutics Inc | Inhibitori kristalne peptid epoksi keton proteaze i sinteza aminokiselinskih keto- epoksida |
US8394816B2 (en) * | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
EP2262812A2 (en) | 2008-03-07 | 2010-12-22 | Nereus Pharmaceuticals, Inc. | Total synthesis of salinosporamide a and analogs thereof |
BRPI0912234A2 (pt) * | 2008-05-12 | 2015-10-06 | Nereus Pharmaceuticals Inc | derivados de salinosporamida como inibidores de proteassomas |
US20110111417A1 (en) | 2008-05-14 | 2011-05-12 | Millennium Pharmaceuticals, Inc. | Methods and kits for monitoring the effects of immunomodulators on adaptive immunity |
CA2740628C (en) | 2008-09-18 | 2018-05-01 | Naurex, Inc. | Nmda receptor modulators and uses thereof |
JP5675629B2 (ja) | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | ペプチドエポキシケトンを用いた併用療法 |
EP2399129B1 (en) | 2009-02-20 | 2015-11-25 | Michael P. Lisanti | A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
EP2305285A1 (en) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Means and methods for treating ischemic conditions |
WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
US20110178287A1 (en) | 2010-01-19 | 2011-07-21 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
KR20130075723A (ko) | 2010-03-01 | 2013-07-05 | 오닉스 세라퓨틱스, 인크. | 면역프로테아좀 저해를 위한 화합물 |
WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
KR20130094185A (ko) | 2010-04-07 | 2013-08-23 | 오닉스 세라퓨틱스, 인크. | 결정성 펩티드 에폭시케톤 면역프로테아좀 저해제 |
HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
WO2013022935A1 (en) | 2011-08-11 | 2013-02-14 | Janssen Pharmaceutica Nv | Predictors for cancer treatment |
CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
CN104302180B (zh) | 2011-10-28 | 2017-05-17 | 米伦纽姆医药公司 | 对nedd8活化酶(nae)抑制剂的反应的生物标记 |
WO2013071163A2 (en) | 2011-11-11 | 2013-05-16 | Millennium Pharamaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
CN104204797B (zh) | 2012-01-24 | 2017-05-31 | 米伦纽姆医药公司 | 治疗癌症的方法 |
US10085987B2 (en) | 2012-01-27 | 2018-10-02 | Thomas Jefferson University | MCT protein inhibitor-related prognostic and therapeutic methods |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
WO2014011695A2 (en) | 2012-07-09 | 2014-01-16 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
CA2886783A1 (en) | 2012-10-01 | 2014-04-10 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods to predict response to inhibitors and uses thereof |
CA2899010A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
CA2899191A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
PE20151427A1 (es) | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
SG11201505860XA (en) | 2013-01-29 | 2015-08-28 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
BR112015018092A2 (pt) | 2013-01-29 | 2017-07-18 | Naurex Inc | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos |
EP2986290A4 (en) | 2013-04-19 | 2017-01-04 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
WO2017201283A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
EA201990428A1 (ru) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | Спиролактамовые модуляторы nmda-рецептора и их применение |
JP2019527232A (ja) | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | スピロ−ラクタムnmda修飾因子及びこれを用いた方法 |
AU2017306158B2 (en) | 2016-08-01 | 2021-10-14 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof |
MX2019001319A (es) | 2016-08-01 | 2019-07-04 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos. |
CN109906218B (zh) | 2016-08-01 | 2023-01-17 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
EP3339291A1 (en) | 2016-12-22 | 2018-06-27 | Vita Api | Proteasome inhibiting ss-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders |
EP3746447A1 (en) | 2018-01-31 | 2020-12-09 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60135469A (ja) * | 1983-12-22 | 1985-07-18 | Tokuyama Soda Co Ltd | 接着性被膜形成材 |
DE3631414A1 (de) * | 1986-09-16 | 1988-03-24 | Basf Ag | Verfahren zur herstellung von (alpha)-pyrrolidonen, deren verwendung und neue (alpha)-pyrrolidone |
US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
US5266588A (en) | 1992-09-25 | 1993-11-30 | Bristol-Myers Squibb Company | Compound produced by a strain of microtetraspora having antibacterial and neuritogenic activity |
US5453502A (en) * | 1994-03-16 | 1995-09-26 | Eli Lilly And Company | 1,3,4 substituted and bicyclic derivatives of 2-azetidinones and processes for preparation thereof |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
-
1995
- 1995-04-12 US US08/421,583 patent/US6335358B1/en not_active Expired - Fee Related
- 1995-06-06 US US08/468,408 patent/US6147223A/en not_active Expired - Fee Related
- 1995-06-06 US US08/466,468 patent/US5756764A/en not_active Expired - Fee Related
-
1996
- 1996-04-12 NZ NZ306775A patent/NZ306775A/xx unknown
- 1996-04-12 AR ARP960102190A patent/AR003415A1/es unknown
- 1996-04-12 WO PCT/US1996/005072 patent/WO1996032105A1/en active IP Right Grant
- 1996-04-12 DE DE69636902T patent/DE69636902T2/de not_active Expired - Fee Related
- 1996-04-12 ES ES96912710T patent/ES2283001T3/es not_active Expired - Lifetime
- 1996-04-12 US US08/945,092 patent/US6645999B1/en not_active Expired - Fee Related
- 1996-04-12 AT AT96912710T patent/ATE353644T1/de not_active IP Right Cessation
- 1996-04-12 KR KR1019970707257A patent/KR100493472B1/ko not_active IP Right Cessation
- 1996-04-12 EP EP96912710A patent/EP0820283B1/en not_active Expired - Lifetime
- 1996-04-12 AU AU55423/96A patent/AU705791C/en not_active Ceased
- 1996-04-12 JP JP53121596A patent/JP4153032B2/ja not_active Expired - Fee Related
- 1996-04-12 CA CA002217817A patent/CA2217817A1/en not_active Abandoned
- 1996-04-12 ZA ZA9602933A patent/ZA962933B/xx unknown
- 1996-04-12 IL IL117887A patent/IL117887A/en active IP Right Grant
- 1996-04-12 CN CNB961947276A patent/CN1151787C/zh not_active Expired - Fee Related
-
1997
- 1997-09-11 US US08/937,228 patent/US6214862B1/en not_active Expired - Fee Related
-
1998
- 1998-03-23 AR ARP980101316A patent/AR014619A2/es unknown
- 1998-03-25 AR ARP980101367A patent/AR011204A1/es unknown
- 1998-03-25 AR ARP980101368A patent/AR012172A2/es unknown
- 1998-07-25 HK HK98109406A patent/HK1008489A1/xx not_active IP Right Cessation
-
2000
- 2000-08-15 US US09/639,242 patent/US6458825B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU705791B2 (en) | 1999-06-03 |
JPH11503732A (ja) | 1999-03-30 |
KR19980703857A (ko) | 1998-12-05 |
HK1008489A1 (en) | 1999-05-14 |
ZA962933B (en) | 1997-02-03 |
AR012172A2 (es) | 2000-09-27 |
EP0820283A1 (en) | 1998-01-28 |
US6335358B1 (en) | 2002-01-01 |
ATE353644T1 (de) | 2007-03-15 |
CN1187769A (zh) | 1998-07-15 |
AU705791C (en) | 2004-08-12 |
IL117887A (en) | 2006-08-20 |
IL117887A0 (en) | 1996-08-04 |
AU5542396A (en) | 1996-10-30 |
AR011204A1 (es) | 2000-08-02 |
DE69636902D1 (de) | 2007-03-29 |
US6214862B1 (en) | 2001-04-10 |
KR100493472B1 (ko) | 2007-04-04 |
DE69636902T2 (de) | 2007-11-22 |
EP0820283B1 (en) | 2007-02-14 |
US6645999B1 (en) | 2003-11-11 |
US6458825B1 (en) | 2002-10-01 |
US6147223A (en) | 2000-11-14 |
WO1996032105A1 (en) | 1996-10-17 |
NZ306775A (en) | 1999-10-28 |
US5756764A (en) | 1998-05-26 |
CN1151787C (zh) | 2004-06-02 |
ES2283001T3 (es) | 2007-10-16 |
CA2217817A1 (en) | 1996-10-17 |
EP0820283A4 (en) | 1998-07-08 |
AR014619A2 (es) | 2001-03-28 |
JP4153032B2 (ja) | 2008-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR003415A1 (es) | Compuestos analogos de lactacistina, metodo para inhibir la proteolisis dependiente de proteasoma, metodo para identificar un proceso biologico mediado por proteolisis dependiente de proteasoma, uso de dichos compuestos para preparar un medicamento para tratar una condicion mediada por proteolisis dependiente de proteasoma. | |
AR004700A1 (es) | 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento | |
AR003938A1 (es) | Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos. | |
AR011069A1 (es) | Compuestos amidino, proceso para su preparacion, compuestos intermediarios, formulaciones farmaceuticas que los comprenden, y su uso en la fabricacion de un medicamento como inhibidor de la oxido nitrico sintasa inducible. | |
AR003116A1 (es) | Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas, composicion farmaceutica que los comprende y el uso de dichos compuestos para la manufactura de medicamentos | |
AR006678A1 (es) | Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion | |
ES2194501T3 (es) | Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen. | |
SE9904505D0 (sv) | Novel compounds | |
BRPI0215312B8 (pt) | composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto | |
AR042262A2 (es) | Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis | |
AR002277A1 (es) | Compuestos utiles como inhibidores de la trombina, composiciones farmaceuticas que los contienen y sustancias peptidicas y peptidomimeticasinhibidoras de la serinproteasa. | |
AR019853A1 (es) | Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci | |
AR019496A1 (es) | Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos | |
AR012294A1 (es) | Derivados de sulfonamida, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen, uso de dichos derivados para lapreparacion de un medicamento. | |
BR9912240A (pt) | Benzocicloheptenos, processo para a sua preparação, preparados farmacêuticos, que contêm os mesmos bem como seu emprego para a preparação de medicamentos | |
ATE45153T1 (de) | Benzisoselenazolthione, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische produkte. | |
DE3783356D1 (de) | Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate. | |
ES2052028T3 (es) | Un metodo para preparar compuestos diarilicos anti-ateroscleroticos. | |
PT839041E (pt) | Sais de derivados de amidina e de inibidor de ciclooxigenase processo para a sua preparacao sua utilizacao como farmacos e composicoes farmaceuticas contendo os referidos sais | |
ES2128043T3 (es) | Uso de bis(amidinobencimidazoles) en la preparacion de un medicamento para inhibir la integrasa retroviral. | |
DE60002126D1 (de) | Substituierte dimere Carboxamid-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen | |
ATE332894T1 (de) | Ein pyridin-n-oxid-derivat und ein prozess zu seiner umsetzung in pharmazeutische wirkstoffe | |
PT1124841E (pt) | Fenil-alcenoil-guanidinas processo para a sua preparacao sua utilizacao como medicamentos ou meios de diagnostico bem como composicao farmaceutica que as contem | |
DE68917937T2 (de) | Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung. | |
AR011437A1 (es) | Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |